Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) Patients During Maintenance Therapy

被引：0
|
作者：
Ungaro, Ryan [1 ]
Jossen, Jacqueline [1 ]
Phan, Becky [2 ]
Chefitz, Ezra
Jain, Anjali [1 ,3 ]
Naik, Snehal [3 ]
Dubinsky, Marla [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Div Pediat Gastroenterol & Hepatol, New York, NY 10029 USA
[3] Prometheus Labs Inc, San Diego, CA USA
[4] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
INFLAMMATORY BOWEL DISEASES | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PD-006
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [11] Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
    Wong, Rochelle
    Qin, Lihui
    Pan, Yushan
    Mahtani, Prerna
    Longman, Randy
    Lukin, Dana
    Scherl, Ellen
    Battat, Robert
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (21)
  • [12] Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
    O'Connell, J.
    McDonagh, P.
    Hazel, K.
    Fiona, J.
    Dunne, C.
    Farrell, R.
    Harewood, G.
    Hartery, K.
    Kelly, O.
    MacCarthy, F.
    McKiernan, S.
    Murray, F.
    O'Morain, C.
    Aoibhlinn, O.
    Kevans, D.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S473 - S473
  • [13] Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, J.
    Sever, N.
    Ferkolj, I.
    Stabuc, B.
    Smrekar, N.
    Kozelj, M.
    Novak, G.
    Gils, A.
    Drobne, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S414 - S414
  • [14] Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kurent, Tina
    Kozelj, Matic
    Novak, Gregor
    Compernolle, Griet
    Tops, Sophie
    Gils, Ann
    Drobne, David
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (06) : 741 - 749
  • [15] VEDOLIZUMAB TROUGH LEVELS AT WEEK 6 PREDICT ENDOSCOPIC AND CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kozelj, Matic
    Novak, Gregor
    Gils, Ann
    Drobne, David
    GASTROENTEROLOGY, 2018, 154 (06) : S819 - S819
  • [16] VEDOLIZUMAB TROUGH LEVELS AND CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Papa, A.
    Ennas, S.
    Di Mario, C.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E99 - E100
  • [17] CLINICAL EXPERIENCE WITH VEDOLIZUMAB TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang Hyoung
    Aniwan, Satimai
    Raffals, Laura H.
    Tremaine, William J.
    Loftus, Edward V.
    GASTROENTEROLOGY, 2018, 154 (06) : S821 - S822
  • [18] Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy
    Parra, Rogerio S.
    Feitosa, Marley R.
    Ribeiro, Leticia C. H.
    Castro, Lais A.
    Rocha, Jose J. R.
    Feres, Omar
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2018, 2018
  • [19] Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease
    Pudilova, K.
    Kolar, M.
    Duricova, D.
    Malickova, K.
    Hruba, V.
    Machkova, N.
    Vanickova, R.
    Mitrova, K.
    Lukas, M.
    Vasatko, M.
    Lukas, M.
    Bortlik, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S356 - S356
  • [20] EARLY VEDOLIZUMAB TROUGH LEVELS ARE NOT ASSOCIATED WITH A SHORT-TERM RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Pudilova, Karolina
    Duricova, Dana
    Kolar, Martin
    Malickova, Karin
    Hruba, Veronika
    Machkova, Nadezda
    Vanickova, Radka
    Mitrova, Katarina
    Lukas, Martin
    Vasatko, Martin
    Lukas, Milan
    Bortlik, Martin
    GASTROENTEROLOGY, 2019, 156 (06) : S877 - S877
12345